ALK and non-small cell lung carcinoma: Based on the results of the ALINA study, alectinib has been shown to be an effective and tolerable adjuvant option for ALK-positive NSCLC, which may also replace chemotherapy and FDA-approved alectinib as a form of adjuvant treatment for ALK-positive non-small cell lung cancer on 18 April 2024, and EMA on 25 April 2024.